Triazole-derivatives as factor xa inhibitors
CA 2526082 C · Owner: Laux, Volker · Inventors: Nazare, Marc; Laux, Volker; Wagner, Michael
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to compounds of the formulae (I) and (II) in , which RO; R1; R3; Q; J1; J2; J3; J4; J5; V; G and M have the meanings indicated in the claims. The compounds of the formulae (I) and (II) are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable for example, for the therapy and , prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa) and can in general be applied in , conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 5, 2004 and granted July 24, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 5, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 5, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.